Shandong Xinhua Pharmaceutical Company Limitedの主要な財務諸表は何ですか?
最新の財務諸表(Form-10K)によると、Shandong Xinhua Pharmaceutical Company Limitedの総資産は$9,019で、純利益は$470です。
SHNXYの主要な財務比率は何ですか?
Shandong Xinhua Pharmaceutical Company Limitedの流動比率は2.23、純利益率は5.55、1株当たり売上高は$12.24です。
Shandong Xinhua Pharmaceutical Company Limitedの収益はセグメントまたは地域別にどのように分けられていますか?
Shandong Xinhua Pharmaceutical Company Limited の最大収益セグメントは Preparation で、最新の利益発表における収益は 4,072,208,527 です。地域別に見ると、China (including Hong Kong) が Shandong Xinhua Pharmaceutical Company Limited の主要市場であり、収益は 6,332,209,258 です。
Shandong Xinhua Pharmaceutical Company Limitedは収益を上げていますか?
はい、最新の財務諸表によると、Shandong Xinhua Pharmaceutical Company Limitedの純利益は$470です。
Shandong Xinhua Pharmaceutical Company Limitedに負債はありますか?
はい、Shandong Xinhua Pharmaceutical Company Limitedの負債は4,028です。
Shandong Xinhua Pharmaceutical Company Limitedの発行済株式数は何株ですか?
Shandong Xinhua Pharmaceutical Company Limitedの総発行済株式数は682.4株です。
主要データ
前終値
$18.19
始値
$18.19
当日レンジ
$18.19 - $18.19
52週レンジ
$18.19 - $18.19
取引高
100
平均取引高
0
配当利回り
--
1株当たり利益(TTM)
0.80
時価総額
$899.9M
SHANDONG XINHUA PHARMACEUTICAL とは何ですか?
Shandong Xinhua Pharmaceutical Co Ltd is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Zibo, Shandong and currently employs 7,296 full-time employees. Shandong Xinhua Pharmaceutical Co Ltd is a China-based company mainly engaged in the development, manufacturing and sales of chemical raw materials, pharmaceutical preparations and chemical products. The firm operates three segments. The Chemical Raw Materials segment is mainly engaged in the development, manufacturing and sales of raw materials for antipyretics and analgesics such as caffeine series, ibuprofen series, aspirin series, dopamine series, barbiturates and pipemidic acid. The Pharmaceutical Preparations segment is mainly engaged in the development, manufacturing and sales of tablets, injections and capsules such as pipemidic acid tablets, aminopyrine and nimodipine tablets. The Pharmaceutical Intermediates and Other Products segment is mainly engaged in the development, manufacturing and sales of pharmaceutical intermediates and other products. The firm mainly operates its business in the domestic market and overseas markets such as the Americas and Europe.